Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial
摘要：Lymphadenectomy is a well established practice for many urological malignancies but its role in renal cell carcinoma is less clear. Our primary objective was to determine whether lymphadenectomy impacted survival in patients with fully resected, high risk renal cell carcinoma.
关键词：kidney; carcinoma; renal cell; lymph node excision; chemotherapy; adjuvant; mortality; ACRIN American College of Radiology Imaging Network; American College of Radiology Imaging Network; AJCC American Joint Committee on Cancer; American Joint Committee on Cancer; ASSURE Adjuvant Sorafenib and Sunitinib for Unfavorable Renal Carcinoma; Adjuvant Sorafenib and Sunitinib for Unfavorable Renal Carcinoma; CCOP Community Cancer Oncology Program; Community Cancer Oncology Program; DFS disease-free survival; disease-free survival; ECOG Eastern Cooperative Oncology Group; Eastern Cooperative Oncology Group; EORTC European Organisation for Research and Treatment of Cancer; European Organisation for Research and Treatment of Cancer; LND lymph node dissection; lymph node dissection; OS overall survival; overall survival; RCC renal cell carcinoma; renal cell carcinoma
论文方向：[{"id":13,"name":"细胞生物学"},{"id":896,"name":"医药科学"}]
发表期刊：The Journal of Urology Volume 199, Issue 1
发表时间：Wed Jan 31 00:00:00 CST 2018
数字识别码：10.1016/j.juro.2017.07.042
是否作者本人： 否
版权及免责声明：
本网站所有论文文件均系用户自行上传或提供，本网站对其内容准确性及合法性概不负责，亦不承担任何法律责任。论文版权归原作者及原出处所有。
如您发现网站其他用户上传的论文有侵犯您的姓名权、隐私权、著作权或其他合法权益现象的，请及时与本网站联系并附加相关权利证明文件，以便本网站及时作出处理，维护您的合法权益。
本网站拥有对此声明的最终解释权。
{replyUser1} 回复 {replyUser2}：{content}